Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: Dalcelli、Exemestane、Gosserine
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Target Recruit Count
- 119
- Registration Number
- NCT06009627
- Locations
- 🇨🇳
Jie Ge, Tianjin, Tianjin, China
A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma
Recruiting
- Conditions
- Pancreas CancerPredictive Cancer Model
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-18
- Target Recruit Count
- 1009
- Registration Number
- NCT05997147
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Drug: Selinexor，Olaparib
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Target Recruit Count
- 49
- Registration Number
- NCT05975944
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Unresectable Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-08-03
- Target Recruit Count
- 20
- Registration Number
- NCT05974059
- Locations
- 🇨🇳
Xuewei Ding, Tianjin, Tianjin, China
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
Phase 2
Not yet recruiting
- Conditions
- PDAC - Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT05947825
Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial
Phase 2
Recruiting
- Conditions
- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
- Interventions
- Drug: Serplulimab+Paclitaxel+ApatinibDrug: Paclitaxel±Ramucirumab
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-07-12
- Target Recruit Count
- 107
- Registration Number
- NCT05942573
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-07-11
- Target Recruit Count
- 29
- Registration Number
- NCT05908747
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
Not Applicable
Recruiting
- Conditions
- HR Positive HER2 Negative Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Target Recruit Count
- 60
- Registration Number
- NCT05890287
- Locations
- 🇨🇳
天津市肿瘤医院, Tianjin, China
Pre-pectoral Breast Reconstruction With or Without Mesh
Not Applicable
Recruiting
- Conditions
- Prepectoral Breast ReconstructionTiLOOP Mesh
- Interventions
- Procedure: prepectoral breast reconstructionProcedure: Tiloop Mesh implantation
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-01-31
- Target Recruit Count
- 164
- Registration Number
- NCT05888571
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: Pyrrolidine、trastuzumab、AI
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Target Recruit Count
- 48
- Registration Number
- NCT05885776
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath